Skip to contentN
Niagen Bioscience, Inc.
N
NAGENiagen Bioscience, Inc. Q2 2019 · 10-Q
Revenue$11.10M$11.10M+42.3% vs Q2 2018 Net Income-$7.76M-$7.76MN/M vs Q2 2018 EPS Diluted-$0.14-$0.14N/M vs Q2 2018 Gross Profit$6,254,000+62.6% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Niagen Bioscience, Inc. · CIK 1386570 · Engraved from SEC EDGAR
Operating Cash Flowderived-$9,021,000N/M Free Cash Flowderived-$9,090,000N/M Margins · derivedGross margin56.3%+7.0 pt vs Q2 2018
Operating margin-64.7%+37.0 pt vs Q2 2018
Net margin-69.9%+33.3 pt vs Q2 2018
ended Jun 30, 2019 · filed Aug 7, 2019 · 38 d after period end